Alithea Genomics Secures $8.9M to Scale RNA Sequencing Technology for Drug Discovery
核心洞察
Alithea Genomics (搜索) closed a CHF 6.9 million ($8.9 million) seed financing round led by Genku Ventures (搜索) to commercialize large-scale RNA sequencing platforms for drug screening and toxicology applications.
The company's 1536-well MERCURIUS DRUG-seq (搜索) kits enable processing of up to 1,536 RNA samples simultaneously, significantly reducing costs and time compared to traditional sequencing workflows.
Funding will support commercialization efforts and development of proprietary transcriptomic data assets to train AI and machine learning models for drug discovery.
Swiss biotechnology company Alithea Genomics (搜索) has completed a CHF 6.9 million ($8.9 million) seed financing round to accelerate commercialization of its large-scale RNA sequencing platforms designed for drug screening and toxicology applications. The round was led by Genku Ventures (搜索), with participation from Novalis Biotech (搜索), Zürcher Kantonalbank (搜索), and several private investors.
The Lausanne-based company, founded in 2020 at EPFL, secured an additional CHF 3 million in this extension round, bringing total seed funding to CHF 6.9 million. The proceeds will primarily fund commercialization of the company's new 1536-well MERCURIUS DRUG-seq (搜索) kits, which enable industrial-scale RNA sequencing for primary drug screening and exploratory toxicology at previously unattainable cost and throughput levels.
Technology Platform Enables Massive Scale
Alithea's platforms, including BRB-seq (搜索) and DRUG-seq (搜索), enable massively multiplexed library preparation solutions for RNA sequencing. The technology allows researchers to prepare hundreds to thousands of RNA samples in a single tube, drastically reducing the cost, time, and resources associated with traditional sequencing workflows.
The 1536-well MERCURIUS DRUG-seq (搜索) kits can process up to 1,536 RNA samples simultaneously, significantly increasing throughput while lowering costs. The company's platforms reduce the time, reagent use, and manual operations typically required for RNA sequencing sample preparation, making large-scale transcriptomic data generation more accessible for pharmaceutical and biotechnology companies.
AI and Machine Learning Applications
Beyond commercialization efforts, Alithea plans to invest in further technology development and the construction of proprietary transcriptomic data assets. The company believes such datasets will play an important role in training artificial intelligence and machine learning models used in drug discovery and predictive biological research.
The RNA sequencing technologies enable researchers to analyze gene expression by sequencing RNA to determine which genes are active under specific conditions, such as disease states or drug exposure. These insights can guide decisions throughout the drug discovery and development process.
Leadership Transition
Concurrent with the funding announcement, Alithea revealed significant leadership changes. Frederik Decouttere has transitioned from Chairman to CEO, while co-founder Riccardo Dainese moves from CEO to Chief Commercial Officer to focus on commercial and business development activities. Kaspar Binz assumes the role of Chairman.
Industry Impact
Jan Van den Berghe, Lead Investor at Novalis Biotech (搜索), emphasized the transformative potential of the technology: "Alithea's technology has reached a level of scalability and data quality that fundamentally changes what is possible in transcriptomics. This is not incremental progress — it is a step-change that unlocks industrial-scale biology for drug discovery, toxicology, and AI-driven research. Our additional investment reflects our conviction that Alithea is becoming the data engine enabling the next generation of therapeutics and predictive biological models."
The company positions its platforms as enabling the generation of large-scale transcriptomic datasets that can support modern biology research, biomarker discovery, and AI-driven therapeutic development, potentially transforming how pharmaceutical companies approach drug screening and toxicology studies.